Please ensure Javascript is enabled for purposes of website accessibility

UM Ventures technology license granted

University of Maryland Ventures, a joint research commercialization effort of the University of Maryland, Baltimore and the University of Maryland, College Park, and Baltimore-based SilcsBio LLC, a supplier of computer-directed drug discovery software and services, announced that SilcsBio has obtained exclusive rights to a technology licensed from UMB.

The technology centers on a computer algorithm for drug discovery.

Financial details of the transaction were not disclosed.

Kelli Booth, SilcsBio’s chief operating officer, said in a prepared statement, “It’s great to have a university so supportive of our state’s start-up community.”

SilcsBio is headquartered at the UM BioPark in Baltimore.